Caplin Point Laboratories Q1 FY27 Results (NSE: CAPLIPOINT)
Signal: Steady quarter
The read
Revenue growth re-accelerates to 19.6% YoY after four quarters of ~10-11%, driven by US scale-up and LATAM tender wins; EBITDA margin expands for 5th straight quarter to 38.4% despite gross margin compression from product mix shift.
| Metric | Value | YoY | QoQ |
|---|---|---|---|
| Revenue | ₹610.36 Cr | 19.6% | 1.7% |
| EBIT | ₹225.41 Cr | 22.1% | |
| Net profit | ₹179.09 Cr | 18.8% | |
| EPS | ₹23.27 | 15.8% | |
| EBIT margin | 38.4% |
P&L walk
Revenue growth accelerated to 19.6% YoY (vs. 10-11% prior quarters) led by US (+26%) and steady Rest of World (+18%); EBITDA margin expanded 70bps YoY to 38.4% despite gross margin compression on product mix shift; PAT grew 18.8% with EPS up 15.8%.
Segments
US segment revenue surged 26% YoY to ₹134 Cr with profit jumping 3.4x to ₹33.3 Cr, driving consolidated growth; Rest of World grew 18% to ₹476 Cr, profit ₹158.4 Cr.
Key positives
- Revenue growth accelerated to 19.6% YoY, highest in recent quarters, led by US segment (+26%) and Rest of World (+18%) with emergency tender wins.
- US segment profit surged 3.4x YoY to ₹33.3 Cr, demonstrating successful scale-up and operating leverage in the regulated market.
- EBITDA margin expanded 70bps YoY to 38.4%, marking the 5th consecutive quarter of YoY margin improvement, supported by cost discipline.
Key concerns
- Gross margin compressed 190bps YoY to 59.8% due to higher share of lower-margin traded goods; this mix shift needs monitoring.
- Cash flow from operations declined 19.5% YoY to ₹95 Cr as higher working capital (receivables 128 days, inventory ₹505 Cr) absorbed profits.
- Receivable days remain elevated at 128 days, indicating credit extension in emerging markets that ties up cash despite strong net cash reserves.
Research and educational content only. Not investment advice.